Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy - Summary - MDSpire

Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy

  • By

  • Liangkui Luo

  • Kaikai Huang

  • Yanbin Pang

  • May 25, 2026

Share

Objective:

To report the rapid hematological response in a young patient with very severe aplastic anemia (VSAA) treated with a combination of high-dose romiplostim, hetrombopag, and immunosuppressive therapy, highlighting its potential significance in improving treatment outcomes.

Key Findings:
  • The patient achieved transfusion independence for red cells and platelets by week 12, suggesting a significant improvement in hematological status.
  • Complete remission was achieved by week 22, with sustained remission at 7 months follow-up, indicating long-term efficacy.
  • The treatment was well-tolerated with only mild adverse effects, supporting its safety profile.
Interpretation:

The combination of high-dose ROMI, hetrombopag, and IST resulted in a rapid and sustained hematological response in a young patient with VSAA who declined HSCT.

Limitations:
  • This is a single case report, limiting generalizability and necessitating caution in applying findings to broader populations.
  • Long-term efficacy and safety of the dual TPO-RA regimen require further investigation to establish its role in standard treatment protocols.
Conclusion:

The findings suggest that the combination therapy may be a promising first-line option for HSCT-ineligible VSAA patients, warranting further research to validate its effectiveness in larger cohorts.

Original Source(s)

Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy

  • by Liangkui Luo, Kaikai Huang, Yanbin Pang

  • May 25, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 13, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Stuart Orkin Awarded Breakthrough Prize in Life Sciences

Stuart H. Orkin, MD, Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, David G. Nathan Distinguished Professor, Harvard Medical School and Investigator, Howard Hughes Medical Institute, has been honored with The Breakthrough Prize in Life Sciences for discovering how the body turns off fetal hemoglobin after birth, a finding that led to a new treatment strategy for sickle cell disease. Dr. Orkin shares the prize with SweeLay Thein, Investigator at the National Institutes of Health (NIH).

  • by

  • April 19, 2026

  • 6 min